KYMR Price Prediction Next Week
Analysis and Insights
To predict the stock price of Kymera Therapeutics (KYMR) for the next trading week, we analyze both technical indicators and recent news sentiment.
Technical Analysis:
- RSI (14-period): 41.37, indicating the stock is in a bearish zone but approaching oversold levels.
- MACD: The MACD line (-0.87) is below the signal line, suggesting bearish momentum.
- Stochastic Oscillator: %K (64.23) and %D (70.49) indicate the stock is oversold, which could signal a potential reversal.
- Fibonacci Levels: The stock is currently testing the lower end of its Fibonacci range, with a pivot point at $33.60, resistance at $35.11, and support at $32.08.
News Sentiment and Analyst Ratings:
- Analyst Consensus: A Moderate Buy rating with an average target price of $60.38, though recent insider selling activity suggests negative sentiment.
- Options Analysis: The $35.00 put contract has a 73% chance of expiring worthless, while the $45.00 call contract has a 45% chance of expiring worthless, indicating moderate volatility.
Price Prediction:
Given the oversold condition and potential for a short-term bounce, the stock may test the $35 resistance level. However, considering the bearish technical indicators and insider selling, the price is likely to decline towards the $32 support level.
Predicted Price for Next Trading Week: $32.00.
Recommendation: Sell.
KYMR Similar Chart Price Prediction
The price of KYMR is predicted to go up 9.36%, based on the high correlation periods with LRFC. The similarity of these two price pattern on the periods is 94.08%.
KYMR
LRFC
Up: 9.36%Similarity: 94.08%
KYMR Revenue Forecast
KYMR EPS Forecast
KYMR FAQs
What is KYMR revenue forecast for next quarter？
What is KYMR eps forecast for next quarter？
KYMR Analyst's Forecast
Geoff Meacham
Citigroup
Strong Buy
2025-03-13
Price Target
$52
Upside
+55.46%
Citi initiated coverage of Kymera Therapeutics with a Buy rating and $52 price target. Healthcare policy remains a key biopharma sector uncertainty but major economic worries have underscored the defensive attributes of biotech, the analyst tells investors in a research note. The firm says that despite near-term "choppiness," a "barbell approach" to the sector still makes sense with higher-growth large caps likely able to absorb potential policy headwinds and catalyst-driven small-cap biotechs being insulated from macro uncertainties. Citi's preferred smaller caps are focused on unmet medical needs, have differentiated research and development platforms or are "clean growth stories." The firm highlights Apogee, Avidity, and Kymera as favorites.
Faisal Khurshid
Leerink Partners
Buy
2024-12-27
Price Target
$60
Upside
+49.59%
Jeet Mukherjee
BTIG
Strong Buy
2024-12-10
Price Target
$60
Upside
+33.19%
